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Ketamine, a dissociative anesthetic commonly used by US physicians, has recently been
shown to be a powerful anti-depressant and is also capable of eliciting transpersonal experiences that can be transformative. Although currently approved in the US only for use as an
anesthetic, physicians there can legally prescribe it off-label to treat various psychological/
psychiatric problems and it has been used for these non-anesthetic purposes in Argentina,
Iran, Mexico, Russia, and the UK, as well as in the US. The literature on using ketamine
psychotherapeutically is reviewed and two case studies using ketamine-enhanced psychotherapy (KEP) for treating death anxiety in terminally-ill people are reported. The potential
importance of beginning formal research on using KEP during end-of-life for those suffering death anxiety is emphasized.

Introduction
he experiential phenomena associated with death
remain unknown. Meanwhile, we all know that
it is the only certainty in life. Everything that
lives dies--with no exception. However, human beings
alone are known to be burdened with the cognitive
capacity to be aware of our own inevitable mortality and
to fear what may come afterwards. A central drive of all
human beings is a self-preservation instinct. Combining
this instinct with the awareness that death is inevitable
creates in some of us a paralyzing terror of non-existence,
which we struggle to overcome through both conscious
efforts and unconscious defense mechanisms. Our death
anxiety may be exponentially intensified during the endstage of any terminal illness when we face death without
refuge. Therefore, it may become necessary to help some
dying people manage death anxiety in such a way that
it resolves existential and other fears related to the endof-life issues. Psychedelic psychotherapy–combined with

T

other conventional treatment approaches–may be a
powerful technique to deal with this challenge, and it
may also be a useful standalone treatment for patients
who have had little to no success with more conventional
approaches.
Numerous clinical research studies of terminallyill patients (e.g., with end-stage cancer) treated with
psychedelic compounds (i.e., primarily lysergic acid
diethylamide [LSD]) were performed from the late
1950s to the early 1970s and sometimes demonstrated
remarkably impressive treatment outcomes (e.g.,
Pahnke, 1968, 1969; Pahnke, Kurland, Goodman, &
Richards, 1969; Pahnke, McCabe, Olsson, Unger, &
Kurland, 1969; Pahnke, Kurland, Unger, Savage, &
Grof, 1970; Pahnke, Kurland, Unger, Savage, Wolf,
& Goodman, 1970; Richards, Grof, Goodman, &
Kurland, 1972; Watts, 1973; Richards, Rhead, DiLeo,
Yensen, & Kurland, 1977; Richards, Rhead, DiLeo,
Grof, Goodman, DiLeo et al., 1979; Grinspoon &
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Bakalar, 1979; Richards, 1979/1980; Grof, 1980; Yensen
& Dryer, 1993/1994; Grob, 1998, 2002; Walsh &
Grob, 2005). Kast pioneered pain treatment with LSD
in patients with terminal cancer by discovering that low
dose LSD (100 micrograms) brought greater analgesia
than more widely used medication (such as Dilaudid
[hydromorphone] and Demerol [meperidine]) and that
these superior effects lasted for several days as opposed to
several hours; in addition, he and colleagues documented
diminished fear of death and significant reduction of
depressive symptoms (Kast, 1962, 1966a, 1966b; Kast
& Collins, 1964). Another investigator replicated Kast’s
findings by treating dying patients with LSD (Cohen,
1965).
The most comprehensive research on LSDassisted psychotherapy on patients with terminal cancer
was done by Pahnke at the Maryland Psychiatric Research
Institute from 1965 through the early 1970s; these studies
asserted that the most powerful results from treatment
were induced by transpersonal (e.g., spiritual, mystical,
or peak) experiences (Pahnke, 1968, 1969; Pahnke et
al., 1969; Pahnke, McCabe et al., 1969; Pahnke et al.,
1970; Pahnke, Kurland et al., 1970). Findings from these
studies indicated that two-thirds of the LSD treated cancer
patients had significant improvement with reductions in
pain, depression, and fear of death.
The final study of that era was done by Grof,
who used LSD-assisted psychotherapy for treatment
of 60 patients with terminal cancer (Grof, Goodman,
Richards & Kurland, 1973). The study measured levels
of anxiety and depression, and the amount of narcotics
before and after LSD treatment. The measures also
included the MMPI and Attitude to Death tests. Grof
reported that 29 percent of his treated patients showed
dramatic improvement, with an additional 41.9 percent
of patients showing moderate improvement.
The medical use of psychedelic substances was
subsequently rejected in the US and most other Western
countries after the onset of the “war on drugs.” This war
emphasized psychedelics’ potential for harm (Cornwell
& Linders, 2002) while overlooking their significant
promise, thus potentially extracting a huge cost on society
as a whole (Miron, 2004). One of the consequences
of the suppression of psychedelic research (with the
exception of ketamine) was an unjustified minimization
of their potential therapeutic value, even though there
is voluminous research literature supporting both the
therapeutic efficacy and safety of psychedelic drugs when
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used by professionals for treating numerous addictive
disorders and mental health problems (Friedman,
2006).
However, this prohibition on research has
changed recently with approval of several US studies of
psychedelic psychotherapy for treating psychological/
psychiatric problems, including those related to terminal
illnesses (Friedman, 2006). One such study at HarborUCLA Medical Center, for treatment of existential anxiety
in end-stage cancer patients, started in 2004 and was the
first known legally-conducted study on this topic after
the decades of prohibition; this study utilizes a psyche
delic agent psilocybin (4-phosphoryloxy-N.N-dimethyl
tryptamine) and was developed and funded by the
Heffter Research Institute (see www.canceranxietystudy.
org). Another study, pending IRB approval at the
Mount Sinai Comprehensive Cancer Center in Miami,
was developed and funded by the Multidisciplinary
Association for Psychedelic Studies (see www.MAPS.
org) to evaluate the effectiveness of psilocybin-assisted
psychotherapy for reduction of distress in patients with
advanced melanoma (personal communication, Sameet
Kumar, April 4, 2007).
Our paper focuses on the clinical potential
of another psychedelic drug, ketamine hydrochloride
(ketamine), which can legally be used by US physicians
to treat psychological/psychiatric problems including
anxieties in dying patients. We present two case studies
on the use of ketamine-enhanced psychotherapy (KEP)
for anticipated grief resolution (AGR) in patients with
end-of-life issues. The first case documents a successful
resolution of anticipated grief outcome after KEP, while
the second case illustrates some of KEP’s limitations.
Overview of Ketamine
The medication ketamine [2-(2-chlorophenyl)2-(methylamino)-cyclohexanone] has many effects
in the brain, but there is now broad agreement that a
key action is its noncompetitive antagonism of the Nmethyl-D-aspartate (NMDA) receptor that modulates
the neurotransmitter glutamate. It produces extremely
effective analgesia and, for more then 30 years, has been
commonly used in clinics and hospitals as an anesthetic
for children, adults, and the elderly due to its rapid onset
and short duration of action. Also due to its exceptional
analgesic properties, ketamine is widely used at subanesthetic doses for management of breakthrough pain
in patients with acute and chronic pain, for treatment of

Kolp et al.

neuropathic pain disorder, ischemic limb pain disorder,
refractory cancer pain, as an adjunct to standard opioid
therapy, and as a pediatric sedation tool for use with
acutely injured children (Petrack, Marx, & Wright, 1996;
Carr, Goudas, Denman, Brookoff, Staats, Brennen et al.,
2004; Ellis, Husain, Saetta, & Walker, 2004; Green &
Krauss, 2004; Howes, 2004; McGlone, Howes, & Joshi,
2004; Rakhee & Milap, 2005; Visser & Schug, 2006).
Ketamine use is devoid of life-threatening
side-effects and several instances of unintentional
administration of overdoses of ketamine–up to ten times
that usually required–have been followed by prolonged
but complete recovery (Physician Desk Reference,
Product Information). All previous clinical studies have
both established its greater safety (e.g., Green & Krauss,
2004; White, Way, & Trevor, 1982) and failed to detect
any long-term impairment as a consequence of its use
(e.g., Siegel, 1978). In fact, there is a plethora of recent
studies investigating the possibility of damage related
to ketamine with normal, pathological (e.g., patients
with schizophrenia), and ketamine-abusing volunteers.
The majority of these studies suggest that ketamine can
be safely used for treatment of various psychological/
psychiatric problems (Morgan, Mofeez, Brandner,
Bromley, & Curran, 2004; Karst, Wiese, Emrich, &
Schneider, 2005; Cho, D’Souza, Gueorgiuieva, Perry,
Madonick, Karper et al., 2005; Parwani,Weiler, Blaxton,
Warfel, Hardin, Frey et al., 2005; Holcomb, Medoff,
Cullen, & Taminga, 2005; Morgan, Rossell, Pepper,
Smart, Blackburn, Brandner et al., 2006).
In addition, more than 7,000 published reports
describe ketamine’s high level of effectiveness in a variety
of other clinical applications (Shapiro, Wyte, & Harris,
1972; Reich & Silvay, 1989; Ross & Fochtman, 1995;
Dachs & Innes, 1997; Bauman, Kish, Baumann, &
Politis, 1999; Green & Krauss, 2000; Ersek, 2004).
According to several reports, ketamine in fact prevents
brain damage from head trauma, strokes, heart attacks,
epileptic seizures, low oxygen levels, and low blood-sugar
levels (Shapiro et al., 1972; Weiss, Goldberg, & Choi,
1986; Rothman, Thurston, Hauhart, Clark, & Solomon,
1987; Shapira, Lam, Eng, Laohaprasit, & Michel, 1994;
Hirota & Lambert, 1996).
The most extensive studies of the biochemical
aspects of ketamine have been done by a US researcher,
Krystal, who has been focusing on its effects on
perceptual and cognitive functioning (Krystal, Karper,
Seibyl, Freeman, Delaney, Bremner et al., 1994). His

group of investigators also completed clinical research
studying the effect of ketamine’s NMDA glutamate
receptor antagonist response in recovering ethanoldependent patients (Krystal, Petrakis, Limoncelli, Webb,
Gueorgueva, D’Souza et al., 2003). In addition, Krystal’s
team reported antidepressant effects of ketamine
(Berman, Cappiello, Anand, Oren, Heninger, Charney
et al., 2000). These antidepressant effects of ketamine
have been recently confirmed by a group of government
investigators at the National Institute of Mental Health
(Zarate, Singh, Carlson, Brutsche, Ameli, Luckenbaugh
et al., 2006), documenting a dramatic improvement in
patients’ mood in a matter of hours among a sample of
eighteen treatment-resistant patients diagnosed with
major depressive disorder. It is noted that these newly
documented powerful antidepressant effects of ketamine
are of great potential importance.
One of us (Krupitsky) has collaborated in
researching the psychopharmacology of ketamine at
Yale with Krystal (Krupitsky, Burakov, Romanova,
Grinenko, Fletcher, Petrakis et al., 2001; Krystal,
Petrakis, Krupitsky, Schütz, Trevisan, & D’Souza,
2003). Krupitsky also conducted independent studies
of ketamine psychopharmacology and biochemistry
(e.g., Krupitsky, Grinenko, Karandashova, Berkaliev,
Moshkov, & Borodkin, 1990) at the Center for Research
in Addiction and Psychopharmacology in St. Petersburg,
Russia, researching the effects of ketamine administration
on metabolism of biogenic amines.
Although there are both widespread medical
usages of ketamine as an anesthetic and significant
ongoing research on many other applications of
ketamine within the US, we know of no current
studies examining this medication’s usefulness for the
treatment of psychological/psychiatric problems. We
are especially concerned that its potential for treating
anxieties related to end-of-life issues has been ignored.
This may be due to the fact that ketamine is seen as a
potent psychedelic agent. It reliably causes powerful
alterations in consciousness (e.g., in mood, perception,
and thought) that naturally occur only during dreaming,
memory flashbacks, psychoses, and mystical experiences
(Rumpf, Pedick, Teuteberg, Munchhoff, & Nolte, 1969;
Grinspoon & Bakalar, 1979; Grinspoon, 1986), and
this is deemed undesirable in the suppressive climate
related to the war on drugs. Nevertheless, given that
many research studies on the clinical effectiveness of
psychedelics are now resuming in the US (Friedman,
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2006), it is an opportune time to conduct further studies
on the effectiveness of ketamine therapy. One fact that
makes ketamine especially appealing as a psychedelic
drug for research and clinical practice is that it is currently
legal for medical practitioners to use in the US now (i.e.,
it can be legally prescribed “off-label”1 by physicians for
psychotherapeutic purposes). This legal status may greatly
facilitate the process of getting approval for ketamine’s
use in formal clinical research, unlike the case with
other psychedelics that require surmounting numerous
bureaucratic hurdles. In addition, there is one other
advantage to ketamine over similar substances, namely
its effects are of short duration and can be managed
within the customary timeframe of most psychological/
psychiatric sessions (i.e., in approximately one hour), so
it can fit into current service delivery systems.
It is also important to emphasize that there
has been an increase of ketamine abuse (Sputz, 1989;
Jansen, 1993). When ketamine is used in uncontrolled
settings recreationally, it can lead to significant medical
problems, including excessive sedation and respiratory
depression–especially if combined with depressants like
alcohol, benzodiazepines, or gamma hydroxybutyrate
(Ricuarte, 2005). Frivolous use of ketamine may also
cause impairment of episodic memory and attentional
functioning (Morgan, Monaghan, & Curran, 2004).
Therefore, we emphasize that ketamine should never
be used in any way other than for research or clinical
applications under the supervision of qualified and
licensed professionals.
Transpersonal Effects of Ketamine
There is no consensual opinion regarding how
psychedelic substances might work beneficially within
clinical settings. Most of the researchers view the active
mechanisms of psychedelic substances solely from a
biochemical perspective. Ketamine is often considered
a “psychomimetic” (i.e., causing effects mimicking
psychoses), prompting some US investigators to use
ketamine-induced phenomena as a model for studying
psychoses in experimental research (e.g., Krystal et al.,
1994). In this model, the psychedelic effects of ketamine
are seen as undesirable rather than as a potential
therapeutic mechanism.
Contrary to this view, we propose that
ketamine’s powerful psychotherapeutic effect is possibly
due to its psychedelic-including transpersonal experience
generating-properties, as it frequently induces in
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sub-anesthetic doses feelings of ego dissolution and
loss of identity, emotionally intense visions, visits to
mythological realms of consciousness, vivid dreams and
memories of possible past incarnations, experience of the
psychological death and rebirth of the ego, and feelings
of cosmic unity with humanity, nature, the universe, and
God. These observable facts were initially described as
“emergence phenomena” (White et al., 1982) and clearly
depict a psychedelic experience. These non-ordinary
states of consciousness offer an additional or alternative
mechanism of ketamine’s effects over and above purely
biological explanations. One of us (Friedman, 2006)
previously speculated that psychedelic drugs such as
ketamine are specifically useful due to their transpersonal,
rather than solely neurobiological, effects. This is also
congruent with the conclusions of numerous researchers
that spiritual factors are crucial in treating many
psychological problems, such as is frequently discussed
for alcoholism (e.g., Robinson, Brower, & Kurtz, 2003;
Amodia, Cano, & Eliason, 2005).
Grof (1980) has developed a comprehensive
theory of psychedelic psychotherapy from this perspective.
He concluded that psychedelic substances facilitate
therapeutic experiences of symbolic death and rebirth of
the ego, allowing clients to work through deep traumatic
fixations in their unconscious. Grof successfully applied
this specific transpersonal psychotherapeutic approach
to more than 750 patients. He explicitly discouraged
his clients from analyzing their psychological problems
and instead assisted them in transcending their inflexible
maladaptive patterns, placing a strong emphasis on their
transpersonal growth potential. Although Grof primarily
used LSD as a psychotherapeutic agent, he acknowledged
that ketamine holds great promise due to its “affinity for
positive dynamic systems” (p. 214). He stated that the
psychoactive effect of ketamine is so powerful that “it
catapults the patient beyond the point of impasse from
the previous LSD session, and can make it possible for
him or her to reach the better level of integration” (p.
214).
There is another specific advantage that ketamine
has over other psychedelic substances (i.e., in addition to
it being legally available through off-label prescription and
of short duration), namely its well-documented ability to
reliably replicate near-death experience [NDE] (Domino,
Chodoff, & Corssen, 1965; Stafford & Golightly, 1967;
Rumpf et al.,1969; Collier, 1972; Siegel, 1978, 1980,
1981; Grinspoon & Bakalar, 1979; White et al., 1982;
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Ghoniem, Hinrichs, Mewaldt, & Peterson, 1985; Lilly,
1988; Sputz, 1989; Kungurtsev, 1991). One of us
(Jansen) analyzed similarities between ketamine-induced
transpersonal experience and NDEs in a series of studies,
concluding that the intramuscular administration of
150-200 mg of ketamine can reliably reproduce all of
the features commonly associated with NDEs (Jansen,
1989a, 1989b, 1990, 1991, 1997, 2001).
The NDE is an altered state of consciousness
usually reported by a person who has experienced so-called
clinical death and has then revived. This is an episode split
off from the patient’s usual life and marked by unusually
intense dream-like events. Typical characteristics of an
NDE include a sense that one is truly dead, a perception
of separation from the body or out-of-body experience,
a sense that what is experienced is real, ineffability or a
sense that the experience is beyond words and cannot be
described using language, and transcendence of time and
space (Ring, 1980, 1984; Greyson, 1983). Some people
believe that they were actually “in death,” reporting
that after “dying” they left their body and floated away,
became enveloped in a dark tunnel, and then entered a
soothing light; later when they “came back to life,” these
individuals are reportedly sometimes able to recall the
events that occurred when they were “dead” (Grof &
Halifax, 1977; Osis & Haraldsson, 1977).
Greyson reported approximately 70 percent of
NDEs are accompanied by feelings of calm and peace,
while about 30 percent of NDEs are very frightening
(Greyson, 1983; Greyson & Stevenson, 1980). These
studies suggest that past memories are often organized
into a life review and patients often report that, during
the NDE episode, their entire past flashes before them.
Transcendent mystical states are also common, with
visions that include meaningful figures (e.g., parents,
teachers, partners, friends, etc.) who may be already
dead or still alive at the time, as well as archetypal images
(e.g., of angels, Buddha, Christ, Krishna, or any other
gods and goddesses) representing patients’ belief system.
The experience of God is often reported as an ocean of
luminescent white light. After effects of NDEs include:
decreased fear of death accompanied by increased
appreciation of life, increased spirituality and concern for
others, and decreased materialism and competitiveness.
Two of us (Jansen and Kolp) had personal NDEs from
natural causes, as well as transpersonal ketamine-induced
experiences, and can verify the striking similarities
between both phenomena (i.e., a sense of being dead, out-

of-body experience, feelings of levitation, transcendence
of time-space continuum, life review, visits of nonphysical realities, encounters with non-corporeal entities,
ineffability of the experience, etc). It is important to note
that the effect and phenomenology of NDEs in children
(who have not yet developed any specific religious
programming) are similar to NDEs in adults (Morse,
Conner, & Tyler, 1985).
NDEs are often very transformative and
can frequently induce positive changes in spiritual
development and worldview (Ring, 1980, 1984; Ring
& Valeriano, 1998). There are also numerous anecdotal
accounts of patients who had a spontaneous remission
of their illnesses (some of them were even classified as
“terminal”) after their NDE (Grey, 1985; Morse & Perry,
1992; Fenwick & Fenwick, 1995; Ring & Valeriano,
1998; Roud, 1990). Ketamine-induced NDEs appear
to be equivalent to natural NDEs and may facilitate
stable recovery by accelerating patients’ psychospiritual
growth and broadening their worldviews (Krupitsky &
Grinenko, 1997).
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History of Ketamine in Psychotherapy
A number of international psychiatric
investigators have utilized treatment with ketamine
to create cathartic effects in psychotherapy. In Iran,
ketamine psychotherapy was shown very effective in
treating various psychiatric disorders (Khorramzadeh
& Lofty, 1973). These investigators administered
ketamine to 100 psychiatric patients with different
mental health and psychosomatic diagnoses, including
depression, anxiety, phobias, obsessive-compulsive
neurosis, conversion reaction, hypochondriasis, hysteria,
tension headaches, and ulcerative colitis. They reported
that 91 participants were doing well after six months,
and 88 remained well after one year. These investigators
concluded that “ketamine’s abreactive or cathartic effect
was related to its mind-expanding qualities;” however,
they did not further specify their findings in clinical
language. In Argentina, Fontana (1974) used ketamine
as an adjunct to antidepressive psychotherapy in order
to facilitate regression to a prenatal level through
a disintegration and death experience, which was
followed with a progression experience that was seen as
similar to a rebirth. He emphasized the advantages of
ketamine, which made it possible to achieve deep levels
of regression. In Mexico, Roquet (1974) was the first
clinician to employ ketamine psychedelic psychotherapy



in a group setting. He combined psychoanalytical
techniques with the healing practices of Mexican Indian
ceremonies and created a new approach to psychedelic
psychotherapy that he called “psychosynthesis” (not
to be confused with the same term used by Assagioli).
He mainly used this procedure to treat neurotic patients,
although he described some success with personality
disorders and selected psychotic patients.
One of us (Krupitsky) first began using ketamine
in the former Soviet Union in 1985 for treatment of
alcoholism. He developed Ketamine Psychedelic Therapy
(KPT) and treated more than 1,000 patients without
complications. In one of his many controlled studies,
nearly 70 per cent of his ketamine-treated patients
remained abstinent from alcohol during a one-year followup, in contrast to only 24 per cent abstinence achieved
in a control group treated with a more traditional form
of therapy (Krupitsky, Grinenko, Berkaliev, Paley, Petrov,
Moshkov et al., 1992). In a comprehensive clinical
research review on this subject, Krupitsky (Krupitsky
& Grinenko, 1997) concluded that KPT is a safe and
effective treatment for alcoholism and other drug
dependencies, such as heroin and ephedrine, as well as
effective for treatment of post-traumatic stress disorder,
reactive depression, neurotic disorders, and avoidant
personality disorders, and somewhat effective for the
treatment of phobic neurosis, obsessive-compulsive
neurosis, and histrionic personality disorder.
Krupitsky and his colleagues (Krupitsky, Burakov,
Romanova, Dunaevsky, Strassman, & Grinenko, 2002)
recently conducted a double-blind randomized clinical
trial comparing the relative effectiveness of high (2.0 mg/
kg IM) to low (0.2 mg/kg IM) dose administrations of
ketamine for the psychotherapeutic treatment of heroin
addiction; two-year follow-up data indicated that high
dose ketamine was more effective. The study reported
that “high dose KPT produced a significantly greater
rate of abstinence in heroin addicts within the first 24
months of follow-up than did low dose KPT” (p. 277).
The authors also concluded that “high dose KPT brought
about a greater and longer-lasting reduction in craving
for heroin, as well as greater positive change in nonverbal
unconscious emotional attitudes” (p. 278). It appears
the study’s data represent both a lower rate of recidivism
and a higher degree of psychological integration. Recent
changes in the regulations governing such research in
Russia have now brought Krupitsky’s pioneering research
efforts to a halt.
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There was also an intriguing study at the
University of Cambridge in the UK, in which ketamine
was used to treat compulsive behavior in young women
with anorexia nervosa with good results, although the
publication of this study does not clearly indicate that
the clinicians used a psychotherapeutic model (Mills,
Park, Manara, & Merriman, 1998.) The study used
infusions of ketamine to treat 15 patients with a long
history of eating disorder, all of whom were chronic
and resistant to several other forms of treatment. Nine
responders showed prolonged remission when treated
with ketamine infusions. Clinical response was associated
with a significant decrease in Compulsion score: before
ketamine, mean +/- SE was 44.0 +/- 2.5; after ketamine,
27.0 +/- 3.5 (t test, p = 0.0016).
There have also been various lone practitioners
in other countries, usually family doctors or psychiatrists,
who have used ketamine to treat psychological/psychiatric
problems (see Jansen, 2001.)
Ketamine-Enhanced Psychotherapy
Inspired by Krupitsky, one of us (Kolp) engaged
in the clinical treatment of alcoholic clients using what
he called Ketamine-Enhanced Psychotherapy (KEP). His
approach was explicitly meant to replicate Krupitsky’s
pioneering work and to extend it into another cultural
context, the US (note: Kolp is a bi-cultural SovietAmerican psychiatrist, who was originally trained as a
Soviet psychiatrist, immigrated to the United States in
1981 and was re-trained as an American psychiatrist). As
with Krupitsky’s KPT technique, Kolp’s KEP treatment
explicitly relied on the transpersonal effects of ketamine
to facilitate psychotherapeutic change. Both researchers
have recently published their combined observations
on clinical and empirical research of the effectiveness
of ketamine-enhanced psychotherapy for treatment of
alcoholism (Krupitsky & Kolp, 2007).
Once more, although most psychedelic drugs
are illegal to use in the US even by physicians, ketamine
is a notable exception because it is readily available to
physicians as an anesthetic that can be legally used offlabel for psychiatric treatment. Consequently, Kolp
employed ketamine in his private psychiatric practice in
the US from the fall of 1996 through the spring of 1999,
administering it to more than 70 clients. Several of us
also recently published Kolp’s empirical observations of
the effectiveness of his KEP for treatment of alcoholism
(Kolp, Friedman, Young, & Krupitsky, 2006).
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During this same period of time, Kolp had an
opportunity to administer KEP to two patients with
end-stage cancer. This paper summarizes these patients’
responses and provides Kolp’s informal retrospective
observations on ketamine’s effectiveness for treatment
of existential anxieties in terminally ill people. We
emphasize that these clinical administrations were not
conducted in a formal research context and this paper
provides the informal retrospective observations on
ketamine’s effectiveness for treatment of existential
anxieties in terminally ill people. However, in light of the
recent resurgence of psychedelic research in the US and
our plans, as a research team, to now seek institutional
review board approval and grant funding for formally
pursuing studies on ketamine’s effectiveness in a number
of clinical applications including the treatment of death
anxiety, a reporting of Kolp’s clinical observations is seen
as warranted.

3 and 5 were 75 to 80 minutes long and session 4
(ketamine-induced near-death experience) was 3 hours
long. During the first three sessions the patient’s beliefs
about “afterlife” and attitudes toward the death were
explored. The patient was told that the psychedelic
session may induce important insights concerning the
above beliefs and attitudes. An individually tailored
“psychotherapeutic myth” was formed during this stage.
During the fourth session the patient was injected
with ketamine and instructed to surrender fully to the
experience. The patient was then exposed to specially
chosen music (generally, New Age composers). During
the final session the patient, with the aid of the therapist,
discussed and interpreted the personal significance of
the symbolic content of the transpersonal experience.
This uniquely profound and powerful transpersonal
experience may help the patient to generate new insights
and attitudes about the death and dying.

Method and Results
KEP was offered to hospice clients for AGR in
order for terminally ill patients to experience a “death
rehearsal.” KEP was administered to clients as part of
a time-limited individual outpatient treatment that
consisted of five sessions administered in the following
stages:

Results from Two Case Studies
In order to illustrate how KEP affected clients
with end-of-life existential issues, two representative
case studies are presented. The first case demonstrates a
success story, while the second case represents a failure
to resolve anticipated grief. These two case studies are
informative for understanding how KEP might be
effective for treatment of anticipated grief resolution,
and they also shed light on factors that can diminish the
therapeutic benefits of KEP.

Session 1
Assessment for appropriateness of treatment with
KEP

The course of treatment was structured on a
weekly basis with one session per week. Sessions 1-

Case Study 1
W developed advanced (stage IV) breast cancer
when she was 62 years old. By the time she was referred
to an oncologist the cancer had already spread to the
bone. She was diagnosed with osteolytic metastases (the
cancer began eating away the bones of her spine, legs,
and pelvis), which caused her persistent skeletal pain. The
oncologist offered her an experimental chemotherapy,
which W initially accepted. However, W learned that
the prognosis of metastatic breast cancer is very poor
and that the treatment with an investigational agent
does not prolong survival time, which is limited to a few
months after diagnosis. In addition, she immediately
developed severe side effects (fatigue, loss of appetite,
nausea, vomiting, worsening of bone pain) and stopped
the treatment after the third intravenous administration.
She was refered to a hospice program for palliative care
and started treatment with an analgesic (morphine, 20
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Session 2
Establishment of a therapeutic alliance and formation
of a psychotherapeutic “myth”
Session 3
Preparation for the transpersonal experience and
formulation of the psychospiritual goal for the
ketamine session
Session 4
Induction of the transpersonal experience through
the administration of 150 mg of ketamine
intramuscularly
Session 5
Integration of the transpersonal experience



mg. orally, every 4 hours), an anti-anxiety medication
(Lorazepam, 2 mg. orally, every 6 hours), and an antiemetic agent (Metoclopramide, 10 mg. orally, 30 minutes
before meals and bedtime). It was at this point that she
requested ketamine-enhanced psychotherapy (KEP) in
order to experience “death rehearsal.”
W shared that she was raised as the only child
in an affluent family and did not have any significant
childhood traumas. Her mother was Roman Catholic
and her father was Unitarian Universalist. W initially
adopted her mother’s religious beliefs, she later changed
to her father’s views (between ages 8 and 9), and in her
early 20s she adopted agnosticism as her primary life
philosophy.
Her substance use history was unremarkable.
W never smoked tobacco and never used any “hard”
drugs. She did not start using alcohol until the age of
21, when she started drinking ETOH very infrequently,
consuming a glass of a table wine, 1-2 times a year. W
reported that she never tried any psychedelic drugs,
including cannabis.
W identified herself as a “sex and love addict.”
She shared that she was sexually awakened at the age of
8 by her 10-year-old cousin, who taught her “the art of
self-pleasuring.” They practiced mutual masturbation in
a variety of forms, on a regular basis (frequently daily),
and, 4 years later, her cousin engaged another participant
in their sexual explorations, an older boy, who was
15 year old at that time. That liaison lasted for a year
until her family moved out of the area. W began dating
independently at the age of 15 and remained very sexually
active through her entire life. She never considered her
sexual behavior to be aberrant or immoral, and she always
unreservedly enjoyed her sexuality.
W reported that she devoted her life-long career
to “a research of human sexuality.” She graduated from
college with a social science degree at age 22 and started
traveling extensively around the world, “sampling men of
all races and colors.” She estimated that she had sex with
more than 5,000 males and approximately 100 females.
She unintentionally became pregnant at age
39, giving birth to a healthy daughter whom she
raised as a single mother. After her daughter started an
exclusive boarding school, W decided to continue her
own education as well and completed a doctorate in
psychology. She became specialized in couples counseling
and continued practicing her specialty until the time of
her terminal illness.



International Journal of Transpersonal Studies

Once W learned her prognosis, she became very
frightened of her impending death. She also became
preoccupied with her childhood religious indoctrinations
and started having uncontrollable fears of “going to the
Hell” as a punishment for her “morbid sin of lust.” She
tried returning to her Catholic roots and even participated
in confession; however, this provided no relief of her
death anxiety. W remained very fearful and apprehen
sive, to the point the she developed frequent “attacks of
terror” several times a day, lasting from several minutes
to half an hour. W continued having daily panic attacks
despite ongoing treatment with an anti-anxiety agent.
W started treatment with KEP within one week
after she terminated her chemotherapy. She spent three
75 to 80 minutes sessions sharing her life history, spiritual
views, and beliefs about afterlife. During the preparatory
stage of her psychotherapy, W was offered the option of
either decreasing or dicontuing the doses of both CNS
depressants (Lorazepam and morphine), in order to
decrease the chance of amnesia and increase the chance
of a mystical experience during KEP. W agreed with this
plan and was successfully detoxified from Lorazepam by
decreasing the dose by 1 mg every 24 hours. She was also
able to gradually decrease the dose of Morphine from 20
mg. 6 times a day to 10 mg. 4 times a day. Moreover, she
completely stopped taking opiates 8 hours prior to the
KEP session. The half-life of morphine is approximately
2 hours; therefore, 8 hours of abstinence from the drug
should have been sufficient time for the opiate to clear
from the patient’s system.
W received 150 mg of ketamine intramuscularly
during her fourth session. This dose induced “a neardeath experience,” which lasted for 50 minutes. She
described the following ketamine-induced transpersonal
experience:
My mind hastily left my body and I found myself in the
heart of nothingness. There weas no space, no time, no
movement, nothing at all. I knew I was dead and felt
disappointed that I did not have a life review. As soon as
I thought about the life review though, I started rapidly
re-living my entire life. I saw my birth, re-experienced
my early childhood and adolescence, witnessed my young
adulthood, and re-lived again my motherhood.
I also re-experienced all my sexual encounters and
love affairs, viewing them not only from my personal
perspective, but also from the point of view of my
partners. I was gratified to know that my sexual behavior
did not hurt my lovers at all. Quite to the contrary, I
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learned that my lovemaking was the source of an intense
pleasure for every one of my paramours and that my gift
of sexual magic enriched their lives.
I then suddenly transcended into my previous lives
and was shown that, from the beginning of Creation,
I was made to be an amorous priestess of love, whose
destiny was to enlighten people through sexuality. I
did not feel that I was being judged whatsoever, and
my shame and guilt were gone instantly. At that very
moment I was swiftly transported into the brilliant
light and felt the presence of my Creator. I sensed–with
a great relief–that Creator is not a god of my mother,
punishing and wrathful, but a benevolent god of my
father - a unified force of Nature. I became clearly
aware that death does not exist and recognized–without
any doubts–I will be re-born again….

Case Study 2
L was a 46-year-old male who had developed a
second attack of cancer. He had his first encounter with
cancer at age 39, when he was diagnosed with bone
cancer (chondrosarcoma of the left lower extremity). L
underwent surgical treatment (amputation of the left leg)
with follow-up chemotherapy and remained symptomfree for almost 7 years.
L developed painless jaundice 2.5 months prior
to his treatment with ketamine-enhanced psychotherapy
(KEP), followed by a diagnosis of advanced pancreatic
cancer that at time of diagnosis had already became
metastatic. He learned that for this type of cancer the
median survival from diagnosis is around 3 to 6 months,
and that the survival improvement with the combination
of all available treatments is on the order of less than four
weeks. L refused the most common surgical treatment
for pancreatic cancers involving the head of the pancreas
and declined both chemotherapy and radiotherapy.
He was accepted by a hospice and it was at that point

that L requested KEP in order to accept his “dying and
impending death.”
L was raised by an interfaith couple. His father
was a Buddhist who shared with L his beliefs in an “afterlife
existence” and “reincarnation of soul.” His mother was
an atheist who did not believe in the existence of soul
and afterlife; she taught L that “we came from the void
and we are to go into the void.” His parents divorced
(due to his mother’s infidelity) when L was 12 years old.
He initially lived with the “party hardy dad” for 2 years
and then moved to live with the “disciplinarian mom”
for the next 4 years. He began living independently at
age 18 and was self-sufficient from that point on.
At the age of 21, L married an older 34-yearold woman after the couple had dated for two years.
They had one son, who was 24-years-old at the time of
his father’s terminal illness. Father and son had a very
distant relationship, and L did not talk with his son for
more than five years. L and his wife divorced six years
after the consummation of the marriage due to his
extramarital affairs. After the divorce was finalized, his
wife was awarded primary custody of the child and L
became a visitation parent. Once the couple divorced,
they stopped communicating with each other.
L was a “hermit” and lived in the “deep
country” in his own rustic dwelling with a breathtaking
view of a lake and tropical jungles. He had lived alone
since age 26 and supported himself by growing and
selling cannabis. Although he had been dealing illegal
substances for many years, he never had any trouble
with law or authorities.
L started using alcohol at age 15 and began
smoking tobacco at 16. Alcohol was never his “cup of
tea,” as he used it only a few times a year and eventually
stopped drinking after age 26. L also stopped smoking
tobacco when he turned 29 (he used to smoke 4-5
cigarettes, 3-5 times a week). His drug of choice became
cannabis, which he started using at age 15 and continued
to use daily, both smoking and eating, throughout the
remainder of his life. L was consuming anywhere from 1
to 2 ounces of cannabis per week. He also “experimented”
with psychedelic drugs and liked them very much,
having “tripped” on LSD more than 200 times, “magic
mushrooms” more than 500 times, and “peyote” more
than 50 times. On several occasions, he also tried DMT,
PCP, and MDMA.
At the time of his KEP, L was taking morphine,
20 mg. 6 times a day, and Xanax, 2 mg. 6 times a day. He
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The following week, during her fifth session,
W happily shared that her persistent pain and recurrent
panic attacks were completely gone and she was able to
discontinue taking both morphine and Lorazepam. She
remained comfortable until her death seven months later
and did not require treatment with either pain-killers or
psychotropic medications. Her daughter later reported
that during the time of her death W was peaceful and
content, and that she died with dignity and smile on her
face.



was also smoking cannabis, 10-12 “joints” a day, and in
addition, was eating 3-4 “brownies” a day (he increased the
consumption of cannabis to more than 2 ounces per week
and moreover started consuming potent hydroponicallygrown “super weed”). L was offered the option to stop
cannabis and decrease the doses of both CNS Depressants
(opiates and Benzodiazepine) in order to increase the
chance of a positive transcendental experience during
KEP; however, L opted to continue taking the above
combination of psychotropic substances.
L had three preparatory sessions in the comfort
of his own home on a one-to-one basis, each session
lasting from 75 to 80 minutes. L then undertook KEP,
with the session lasting about 3 hours. L described his
ketamine-induced experience as follows:
As soon as drug started working, my mind separated
from my body and, in turn, started going into oblivion.
I realized I am dying and a strong fear of nonexistence completely overwhelmed me. My mind was
finally gone and I was sucked into an infinite ocean of
unconditional sorrow. Some part of me–the one of an
observer–continued existing; however, it began decaying
as well. I died as a human many times, each time from
different causes, somehow re-incarnating again, each
time regressing on a lower level. I then started dying
and re-incarnating as a mammal, again regressing
from higher forms to lower ones, next as a bird, after
that as a fish, and so on, until I became a primordial
protoplasm, at which point I blacked out. Only when
the drug stopped working did I recognize that I was still
alive. It was the worst bummer (a bad “trip”) I’ve ever
had….
During the last follow-up session L continued
verbalizing his horror of disintegration all through
his frightening experience of stepwise regression from
existence to non-existence. Although he used the word
“re-incarnation” (most likely a residue of his father’s
religious beliefs), L utilized this word to describe a slow
and painful death, not a proof of life after death. He also
repeatedly stated that he “now knows for sure his mom
was right when she taught there is no life after death.”
L was offered additional follow-up sessions; however,
he declined any further treatment. L continued using
his drug cocktail in escalating doses and died less than
2 weeks after our last session–alone, disheveled, and
soiled–probably from the accidental overdose of the CNS
depressants.
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Conclusion
Due to ketamine’s availability for off-label
medical use in the US, its short duration of action that
fits well into the current delivery system, and its long
history of successful clinical applications in treating a
variety of mental health problems outside of the US,
it presents itself as an ideal psychedelic to research the
effectiveness of psychedelic psychotherapy in the US.
In addition to biochemical mechanisms that might
explain its possible efficacy for treating a wide range
of psychological/psychiatric problems, its presumed
ability to reliably replicate experiences that are to a
large extent similar to NDEs provides a plausible
transpersonal mechanism for its possible efficacy. Due to
its relationship to NDEs, ketamine may be particularly
helpful for treating death anxiety in those with terminal
illnesses, namely by providing an opportunity for a direct
experience of personal existence as a non-physical being
that aids decision-making and powerful experiential
shifts in attitudes toward death and dying. In addition,
NDEs are well known to induce dramatic psychological
transformations in people, so ketamine-induced NDEs
may also have the potential to successfully help dying
people overcome their existential anxieties as well
as to treat various psychological problems, addictive
illnesses, and psychiatric disorders. It should be pointed
out, however, that we believe a ketamine-induced
psychedelic experience has no beneficial effect in and of
itself. In fact, when ketamine is used in uncontrolled
settings recreationally, it can lead to significant medical
problems (Ricuarte, 2005). We firmly believe that the
therapeutic relationship, as well as set (i.e., patient’s
expectations toward the experience) and setting (i.e.,
context surrounding the experience), are paramount to
the effectiveness of ketamine-enhanced psychotherapy
(KEP). In order for the KEP sessions to cause positive
transformative experiences, it is extremely important
to carefully prepare patients for the KEP session, to
attentively supervise them during the session, and to
provide psychotherapy after the session to facilitate
the integration of the ketamine-induced transpersonal
experience and to help patients personally accept insights
gained during the KEP session. Previous work by
Krupitsky and Grinenko (1997) demonstrated the added
value of ketamine above and beyond set and setting;
the control group of the patients with the same set and
setting who were injected with a placebo did not gain
the same benefits as compared to the group of patients

Kolp et al.

receiving ketamine. For these reasons KEP is a specific
psychotherapeutic technique structured to incorporate
the therapeutic relationship, set, and setting to achieve
maximal benefits.
In a previous paper some of us reported that
clients who failed to respond well to ketamine treatment
of alcoholism seemed to have a history of severe control
issues and/or persistent difficulties in maintaining longterm interpersonal relationships (Kolp et al., 2006).
From the first case study presented in this paper, we at
least partially attribute the woman’s positive treatment
outcome to the fact that she never tried any psychedelics
previously (a novelty factor) and had positive
expectations or set toward it. She was also willing to
stop benzodiazepine while decreasing her use of opiates,
which made the experience stronger. On the other hand,
from the second case study we hypothesize that the man’s
negative treatment outcome was due at least in part
to his extensive history of psychedelic use (i.e., it was
just “another bad trip” for him) and his unwillingness
to stop, or at least decrease, his sedative medications
(benzodiazepine and opioids) before the ketamine
session. It is noted that both of these CNS depressants
diminish an individual’s response to ketamine and can
cause amnesia of the event. They may also negatively
affect ketamine-induced transpersonal experiences due
to over-sedation. Therefore, we recommend reducing or
eliminating use of these substances by patients prior to
any future therapeutic clinical applications of ketamine.
Perhaps they should now even be considered as a possible
contra-indication for ketamine-enhanced psychotherapy.
In addition to set and setting, we also learned from these
two patients, as well as from some of our prior research
with alcohol abusers, that the novelty of the psychedelic
experience may be salient for successful problem
resolution. Psychedelics are indeed a unique class of
drugs that produce intense effects unlike those of other
drugs–and one’s first “trip” can therefore be a profound
and life-changing experience (as common wisdom says,
“there is no second chance for the first impression”). For
those with extensive histories of psychedelic use, however,
there is a diminished chance that a ketamine experience
will be all that unique and transformative, whereas for
the novice psychedelic user, given proper set and setting,
the experience can be profound.
Consequently we conclude that KEP used
adjunctively within a carefully crafted set and setting
does appear to be a promising technique for successful

resolution of anticipated grief for patients in the US. Of
course, with informally gathered case studies and no use of
control groups or blinds (i.e., placebos), nothing definitive
can be concluded about the generalized effectiveness of
KEP from these observations. In addition, any possible
conclusions are further compromised because these data
were presented and analyzed in a retrospective manner
without the benefit of written records to substantiate
them. Nevertheless, based on the solid research on
ketamine’s usefulness in psychotherapy conducted by
several international research studies, it is interesting to
speculate that KEP may be successfully used in this way
within the US for AGR. Additionally, the case studies
strongly suggest that a transpersonal explanation for
KEP’s possible efficacy may be warranted along with
biochemical explanations.
In order to explore the possible usefulness of
KEP in the US more fully, beyond what appears to be
some initial clinical success (and suggested limitations)
made by Kolp in his practice, we note it is crucial to
replicate these results in larger, well-controlled studies.
We have designed the protocol of a prospective singlesite, double-blind, placebo-controlled, randomized,
parallel group clinical trial of the efficacy of KEP for
treatment of existential anxieties in hospice patients with
end-stage cancer. Following patient selection and consent
procedures, it is planned that clients will receive one
session with ketamine or placebo on the fourth sessions of
standard outpatient treatment with outcomes measured
at baseline before KEP and then one, three and six months
following discharge. One unique aspect of our planned
study is that we explicitly hypothesize that transpersonal
factors, such as changes in level of self-expansiveness
(Friedman, 1983) and spirituality (MacDonald, 2000),
are among the essential mechanisms in KEP’s possible
efficacy and we intend to carefully measure transpersonal
variables in a standardized fashion, along with other
important factors.
Another potential area of future research is to
explore the similarities between ketamine-induced NDEs
and NDEs triggered by natural causes, such as from
injuries, strokes, heart attacks, epileptic seizures, low
oxygen levels, low blood-sugar levels, and other similar
factors. Perhaps one useful strategy for future study
would involve the administration of a psychedelic dose of
ketamine to persons who have previously had a “natural”
NDE. Psychological measures collected before the
administration of ketamine in order to determine some
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baseline information about the past NDE, along with
the same measures collected after the ketamine-induced
NDE, could be used to compare both experiences.
The fact that ketamine is an FDA approved
pharmaceutical and can now be legally prescribed offlabel does circumvent many of the prejudicial concerns
against conducting research that affects most other
psychedelics in the US. Ketamine’s lawful availability
avoids the complex bureaucratic morass that must be
navigated in researching other psychedelic substances, a
process in which simply obtaining stringently restricted
drugs for research purposes can take years to negotiate. In
addition, the recent lifting of the ban on formal research
on psychedelics in the US, which has opened the way for
a number of important psychedelic studies that are now
being conducted at major US universities (Friedman,
2006), leads to an exciting opportunity for expanding
the already impressive line of therapeutic studies utilizing
ketamine for treatment of addictive and mental disorders.
Further, the recent study conducted by investigators
at the National Institute of Mental Health (Zarate et
al., 2006) reporting ketamine’s positive effects among
treatment-refractory patients with major depressive
disorder adds to the legitimacy of examining ketamine’s
psychotherapeutic potential. The possible importance of
psychedelics may lie in their ability to foster transpersonal
experiences and not just on their neurobiological effects
(Friedman, 2006). If transpersonal experiences can
be further demonstrated both to be reliably produced
through psychedelics, including ketamine, and to have
salutary effects, this could dramatically change the way
that many psychological and psychiatric conditions are
treated. This could have broader social implications,
such as a diminishment of the fervor, stemming in part
from the fear of powerful transpersonal experiences, that
at least partially contributes to the war on drugs now
vigorously pursued within many contemporary Western
societies.
In regard to using ketamine to treat death anxiety,
given the current mandate for outcome-based treatments
that are time-limited as dictated by third-party payers,
further research into exploring the potential of ketamine
is very important. In addition, in this era of non-clinical
constraints based upon financial interests, the possibility
of developing an effective treatment approach that is costeffective, limited to a few sessions, and that facilitates the
reduction of costly restrictive drugs while simultaneously
alleviating pain and increasing peace, has tremendous
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appeal. Whether the intrinsic value of psychedelic
therapies is viewed from the financial aspect or from the
more humane aspect, we believe there is tremendous
value in pursuing further research that may alleviate the
pain of those suffering with the final emotional hurdles
of surrendering both peacefully and mindfully to the
inevitable.
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